Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Avalyn Pharma Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
AVLN
Nasdaq
2830
www.avalynpharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Avalyn Pharma Inc.
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
- Sep 8th, 2026 6:00 am
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
- Sep 8th, 2026 6:00 am
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
- Aug 24th, 2026 2:01 pm
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Aug 12th, 2026 6:00 am
What It Means To Hold Moderna Stock In A Crash
- Jul 13th, 2026 7:12 am
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
- Jun 17th, 2026 6:00 am
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
- Jun 5th, 2026 8:06 pm
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
- Jun 3rd, 2026 5:00 am
Assessing Avalyn Pharma (AVLN) Valuation As Investors React To Recent Share Price Moves
- Jun 1st, 2026 2:08 pm
Avalyn to Participate in the Jefferies Global Healthcare Conference
- May 27th, 2026 6:00 am
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
- May 21st, 2026 6:00 am
Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- May 1st, 2026 2:01 pm
Avalyn Announces Pricing of Upsized Initial Public Offering
- Apr 29th, 2026 7:00 pm
Scroll